medRxiv 预印本· Rehman, S. M., Shetty, R., Magdalene, C. M., Panda, M., Ganesh, J. S., Gupta, R., Murugan, S., L. Ramprasad, V., N Dhabar, B., Patil, S., Kapoor, A., Aggarwal, S., Patil, T., Pai, A., Prasad, K., Mishra, S. K., Sathyanarayanan, V., Pramanik, R., Gupta, A., Sansar, B. ·· 15 天前AI 评分38
MedGenome 自研 HRD 检测 MG_HRD 在卵巢癌中验证并落地,与商业化检测总体一致率 97.1%
Analytical Validation and Clinical Implementation of MedGenome HRD Assay: A Large Comparative Study Against Commercial HRD Assays in Ovarian Cancer
AI 导读
MedGenome 基于 4,163 例卵巢癌 FFPE 样本开发并验证自研 HRD 检测 MG_HRD,与商业化检测总体一致率 97.1%、NPA 98.3%、PPA 96.4%,在 Myriad 子集外测中完全一致。
来源:medRxiv 预印本 · medrxiv.org